In vitro experiments have demonstrated that deficiency in HR by mutations in MRE11-RAD50-NBS1 (MRN) complex may sensitize cancer cells to treatment with PARP inhibitors [24–26] and might therefore serve as a predictive biomarker of PARP inhibitor therapy. This evidence concerns the gene MRE11 and cancer.